Thomas Gabrielczyk

1 week ago | european-biotechnology.com | Thomas Gabrielczyk

The newly released study finds that the performance of bioreactors used in the production of meat alternatives doubles approximately every 3.6 years. China is leading in technology development, holding four of the top five patent positions in the key technologies for cultivated meat. One of these patent holders is a US-based company. A report published in April by the US National Security Commission on Biotechnology warns that the US must invest at least US$15bn in biotechnology by 2031.

1 week ago | european-biotechnology.com | Thomas Gabrielczyk

“Despite unprecedented scientific advances, many oncology treatments still face hurdles at the funding stage,” said Julita Balcerek, Ph.D., COO at Mabion. “This contest is our invitation to innovators who just need the right partner. We’re offering more than a prize; we’re offering a path to impact”. Selected entrants will be guided through pre-qualification, NDAs, and proposal shaping with Mabion’s business development team.

2 weeks ago | european-biotechnology.com | Thomas Gabrielczyk

Similar to GEA’s initial scaling facility for cell-based food production in Germany, the recently opened 10,000-square-metre facility in Janesville, Wisconsin is intended to assist scientists and entrepreneurs in the developing food technology sector to increase their production to industrial levels. With a 40% market share and a thriving start-up scene, the US is ahead of both Europe (30%) and Asia (20%).

2 weeks ago | european-biotechnology.com | Thomas Gabrielczyk

Bad news for the manufacturers of the weight loss pills Zepbound and Wegovy, which brought Elli Lilly and Novo Nordisk combined sales of US$12.9bn in 2024? Scientists at the Max Planck Institute for Metabolism Research have discovered a new network of nerve cells in rodent models that evokes a feeling of satiety when smelling food in normal-weight mice, but not in obese mice – a new therapeutic approach?

2 weeks ago | european-biotechnology.com | Thomas Gabrielczyk

SpliceBio SL will use the US$135m Series B cache injection to advance Phase I/II trials of its lead compound SB-007 in the retinal disorder Stargardt disease, namely the interventional ASTRA study launched in March and the observational POLARIS study. In the Series B new investors EQT Life Sciences and Sanofi Ventures joined the investment team of  Roche Venture Fund and New Enterprise Associates, UCB Ventures, Ysios Capital, Gilde Healthcare, Novartis Venture Fund, and Asabys Partners.